---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125347"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:24.747681+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Korro Bio reports Q3 net loss $21M, cash $169.1M; files clinical study for KRRO-110, partners Novo Nordisk

## Summary
- Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).
- Cash and equivalents $169.1M as of Sep 30, 2024; cash runway into H2 2026.
- Submitted regulatory filing in Australia for Phase 1/2 study of KRRO-110 in AATD; first dosing expected Q1 2025.
- Announced collaboration with Novo Nordisk for up to two targets in cardiometabolic diseases; up to $530M in milestones plus royalties.
- Appointed Jeffrey Cerio as General Counsel, Katharine Knobil to Board; formed Clinical Advisory Board.

## SEC filing metadata
- accession: 0000950170-24-125347
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/0000950170-24-125347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/krro-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125347
- JSON: https://secwatch.observer/filing/0000950170-24-125347.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.